Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Clinical Psychopharmacology and Neuroscience ; : 559-563, 2019.
Artículo en Inglés | WPRIM | ID: wpr-763562

RESUMEN

Schizophrenic patients resistant to antipsychotics are diagnosed as having treatment-refractory schizophrenia, and they are treated with clozapine. However, clozapine is sometimes combined with electroconvulsive therapy (ECT) if clozapine monotherapy fails. In this report, a severe treatment-refractory schizophrenic patient who did not respond to clozapine even with ECT, but who recovered with asenapine monotherapy, is presented. Asenapine, considered a serotonin spectrum dopamine modulator, is a new atypical antipsychotic with unique pharmacological features that is used not only for schizophrenia, but also for bipolar disorder. The unique features of asenapine may be effective for some treatment-refractory schizophrenic patients.


Asunto(s)
Humanos , Antipsicóticos , Trastorno Bipolar , Clozapina , Dopamina , Terapia Electroconvulsiva , Recurrencia , Esquizofrenia , Serotonina , Suicidio
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA